---
title: "ArriVent BioPharma, Inc. Stock 12‑Month Price Target Cut to $37.55, Implies 32% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301081225.md"
description: "ArriVent BioPharma's average 12-month price target was cut to $37.55 from $42.45 by 11 analysts, implying a 32% upside based on the Oct. 5 close. Despite the reduction, the consensus rating remains 'Buy' with no Holds or Sells."
datetime: "2026-10-06T22:20:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301081225.md)
  - [en](https://longbridge.com/en/news/301081225.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301081225.md)
generator: "portal-rs"
---

# ArriVent BioPharma, Inc. Stock 12‑Month Price Target Cut to $37.55, Implies 32% Upside

-   According to estimates from 11 analysts, ArriVent BioPharma, Inc. stock's average price target has fallen from $42.45 to $37.55, with forecasts ranging from $18 to $50 per share
-   Based on the Oct. 5 closing price, the updated target implies approximately 32% potential upside
-   Consensus rating remains at “Buy” across 12 covering analysts, with 12 Buys, 0 Holds and 0 Sells

Explore more price target data and ratings for ArriVent BioPharma, Inc. on the , and track all previous and future analyst recommendations for ArriVent BioPharma, Inc. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [AVBP.US](https://longbridge.com/en/quote/AVBP.US.md)

## Related News & Research

- [ArriVent doses first patient in Phase 1 trial of ARR-002 dual-target ADC for ovarian, endometrial cancer](https://longbridge.com/en/news/301620875.md)
- [ArriVent BioPharma Lung Cancer Drug Fails Primary Trial Endpoint, Stock Hits 52-Week Low](https://longbridge.com/en/news/301066580.md)
- [ArriVent BioPharma Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into ArriVent BioPharma (AVBP)](https://longbridge.com/en/news/301079950.md)
- [ArriVent says Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC misses primary PFS endpoint](https://longbridge.com/en/news/301032671.md)
- [Bank of America Q3 Preview: Stock Down in 2026, Could 5th Straight Double Beat Change Momentum?](https://longbridge.com/en/news/301739892.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**